Posts

Posted on

Victory Square Technologies Portfolio Company Enters Into Sales & Distribution Contract with Brazilian Company for an Initial Order of 3.7 Million Covid-19 Rapid Tests for Brazil

  • This sales and distribution contract between Victory Square Health and the Brazilian production and distribution company will provide the company with an initial order of 3.7 million Covid-19 Rapid Tests over the next 24 months
  • This agreement is in addition to the previously announced business development and sales agreement with Molkom Pharmaceuticals on November 18, 2020

VANCOUVER, British Columbia, Dec. 14, 2020 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company“) (CSE:VST) (OTC:VSQTF) (FWB:6F6) — portfolio company Victory Square Health (VSH) has entered into a new sales and distribution contract with a Brazilian medical production and supply company on December 14, 2020. The contract will provide for an initial order of 3.7 million Covid-19 Rapid Tests to be supplied from Victory Square Health subject to ANVISA approval. The order is to be filled over a 24-month period.

“This newly announced 3.7 million unit contract for our Covid-19 Rapid Testing kits is an important new sales agreement as we ramp up production supply to Brazil,” said Felipe Peixoto, CEO of Victory Square Health. Peixoto goes on to say, “We are confident that this order will provide the country of Brazil with critical and accurate assistance in identifying and fighting this pandemic while also generating further sales opportunities for VSH in Brazil.”

Today’s announced sales and distribution agreement is in addition to the business development & sales agreement with Molkom Pharmaceuticals announced on November 18, 2020. Molkom has established strong relationships throughout South America and beyond with strategic business connections with distributors, sales supply chains, retail pharmacies, hospitals, and with agencies at all level of government. The Company’s strategic business & sales agreement with Molkom Pharmaceuticals has opened doors to access new sales and supply leads and has been successful with the company’s announcement of today’s 3.7 million unit sales contract.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.


Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Check out VictorySquare.com and sign up to VST’s official newsletter at



www.VictorySquare.com/newsletter

On behalf of the board,

Shafin Diamond Tejani
Chief Executive Officer
Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios

Email: [email protected]

Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director

Email: [email protected]

Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.

VST’s sweet spot is the cutting-edge tech that’s shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn’t just another investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors

VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they’re unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.



Posted on

Marimaca Copper Files Preliminary Base Shelf Prospectus

Not for distribution to United States newswire services or for dissemination in the United States

VANCOUVER, British Columbia, Dec. 14, 2020 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (“Marimaca Copper” or the “Company”)(TSX: MARI) announced today it has filed a preliminary short form base shelf prospectus with the securities regulators in each province of Canada, except for the Province of Quebec. When made final, the prospectus will allow the Company to offer up to $100 million of common shares, warrants, units, subscription receipts or any combination thereof (“Securities”) during the 25 month period that the shelf prospectus is effective. The specific terms of any offering of Securities, including the use of proceeds from any such offering, will be set forth in a shelf prospectus supplement.

Marimaca Copper has filed the shelf prospectus in order to provide the Company with greater financial flexibility going forward, but has no immediate plans to offer or issue any Securities at this time.

The shelf prospectus filed with the Canadian securities regulators has not been made final. Securities may not be sold pursuant to the shelf prospectus prior to the prospectus becoming final. A copy of the preliminary short form base shelf prospectus can be found on SEDAR at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of any such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. The Securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such Securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.

Contact Information

For further information please visit www.marimaca.com or contact:

Tavistock

+44 (0) 207 920 3150

Jos Simson/Emily Moss
[email protected]

Forward Looking Statements

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. These statements relate to future events or the Company’s future performance, business prospects or opportunities. Forward-looking statements include, but are not limited to, the anticipated use of the net proceeds from the sale of the Securities, anticipated advancement of the Company’s Marimaca Project and future exploration and development plans of the Company. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by Marimaca Copper, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: risks related to share price and market conditions, the inherent risks involved in the mining, exploration and development of mineral properties, the uncertainties involved in interpreting drilling results and other geological data, fluctuating metal prices, the possibility of project delays or cost overruns or unanticipated excessive operating costs and expenses, uncertainties related to the necessity of financing, the availability of and costs of financing needed in the future as well as those factors disclosed in the annual information form of the Company dated April 8, 2020, the preliminary short form base prospectus and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Accordingly, readers should not place undue reliance on forward-looking statements. Marimaca Copper undertakes no obligation to update publicly or otherwise revise any forward-looking statements contained herein whether as a result of new information or future events or otherwise, except as may be required by law.

Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.



Posted on

Thinking about trading options or stock in General Electric, Carnival Corp, United Airlines, Electrameccanica Vehicles, or Workhorse Group?

PR Newswire

NEW YORK, Dec. 14, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for GE, CCL, UAL, SOLO, and WKHS.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-general-electric-carnival-corp-united-airlines-electrameccanica-vehicles-or-workhorse-group-301192093.html

SOURCE InvestorsObserver

Posted on

Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals?

PR Newswire

NEW YORK, Dec. 14, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-inseego-corp-ampio-pharmaceuticals-marathon-patent-group-regulus-therapeutics-or-biocryst-pharmaceuticals-301192087.html

SOURCE InvestorsObserver

Posted on

Thinking about trading options or stock in Tesla, American Airlines, Royal Caribbean Cruises, Alibaba, or Apple?

PR Newswire

NEW YORK, Dec. 14, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for TSLA, AAL, RCL, BABA, and AAPL.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-tesla-american-airlines-royal-caribbean-cruises-alibaba-or-apple-301192095.html

SOURCE InvestorsObserver

Posted on

Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.

“We appreciate the confidence the Ministry of Health of Singapore has demonstrated in our mRNA vaccine platform by including mRNA-1273 in their portfolio of vaccines. We recognize that addressing this global pandemic will require a number of vaccines and therapeutic options, and we are proud of the role Moderna has been able to play in this global effort,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We continue to advance the clinical development of mRNA-1273 and the recent positive primary efficacy analysis from our Phase 3 COVE study is an encouraging step forward as we work together to address this global health emergency by delivering a vaccine to the people of Singapore and around the world.”

The data from the Phase 3 COVE study involving 30,000 participants demonstrated efficacy of 94.1% against COVID-19 and 100% against severe COVID-19. Efficacy was consistent across age, race and ethnicity, and gender demographics in the 196 observed cases of COVID-19. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). Based on prior analysis, the most common solicited adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose. The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. Moderna plans to submit data from the Phase 3 COVE study to a peer-reviewed publication.

Moderna recently announced data showing that mRNA-1273 remains stable at 2° to 8°C (36° to 46°F), the temperature of a standard home or medical refrigerator, for 30 days. Stability testing supports this extension from an earlier estimate of 7 days. mRNA-1273 remains stable at -20° C (-4°F) for up to six months, at refrigerated conditions for up to 30 days and at room temperature for up to 12 hours. Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021.

Over the past nine years, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. The investments in this proprietary platform have enabled Moderna to expeditiously create, manufacture and clinically develop mRNA-1273 to potentially address the current COVID-19 pandemic.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s development of a potential vaccine against the novel coronavirus, the potential for mRNA-1273 to prevent COVID-19 disease and slow the spread of SARS-CoV-2, the safety profile for mRNA-1273, plans for the supply of mRNA-1273 to the Ministry of Health of Singapore, plans for the manufacturing and distribution of mRNA-1273, and the conditions under which mRNA-1273 can be shipped, stored and administered. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of mRNA-1273 observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for mRNA-1273; whether and when any biologics license applications and/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Moderna:

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

[email protected]

Investors:

Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]

KEYWORDS: Massachusetts China United States North America Asia Pacific

INDUSTRY KEYWORDS: Other Health Professional Services Pharmaceutical Medical Devices Infectious Diseases Fitness & Nutrition Other Professional Services Clinical Trials Biotechnology Medical Supplies FDA Health

MEDIA:

Logo
Logo
Posted on

Canadian Live Music Association and Kinaxis Announce Live Concert Series to Help Sustain Hard-Hit Music Industry

Canada NewsWire

Kinaxis InConcert to sponsor up to 30 concerts supporting artists in diverse music genres across Canada

OTTAWA, ON, Dec. 14, 2020 /CNW/ – Canada’s live music community has received an early holiday gift thanks to the generosity of Ottawa-based supply chain software company, Kinaxis® Inc. (TSX: KXS). Today, the Canadian Live Music Association (CLMA) and Kinaxis unveil details of Kinaxis InConcert, a new performance series that will feature approximately 30 concerts live streamed from stages across Canada. The concert series will be funded via a $250,000 sponsorship from Kinaxis and facilitated through an application process available to all professional live music venues. Applications to KinaxisInConcert will be accepted beginning today through February 28, 2021 at: kinaxis.com/InConcert.

“We are grateful to Kinaxis for setting an example of the kind of private sector support that Canada’s live music community desperately needs,” says CLMA president and CEO, Erin Benjamin. “Kinaxis InConcert is a reason to come together to celebrate our artists, support our venues and connect to music fans. It is much needed good news for an industry that has suffered unprecedented economic hardship.”

Canada’s live music industry is facing seismic threats to its sustainability. Venues are closing their doors at an alarming rate leaving countless Canadians who benefit culturally and financially from this sector in a precarious situation. According to a recent study conducted by Nordicity, each venue that closes costs an average of $575,000 in annual GDP contributions, and $148,000 in provincial and federal taxes.

“The Kinaxis culture is anchored on the simple words ‘people matter here’. This extends to the communities where we live, work and play,” said John Sicard, CEO of Kinaxis. “Sadly, the people supporting our music industry, and especially the artists themselves, have been tremendously affected by the restrictions resulting from COVID-19, and that means we miss out on the joy they create through their live performances.”

Artists who rely on live music venues have been vocal about the support needed by the sector. Venues such as Roy Thomson Hall, deCoste Performing Arts Centre, La Sala Rossa, festivals, and clubs like Commodore Ballroom, Starlite Room and Horseshoe Tavern are essential to the cultural life in every city across Canada.

“Performing is not just about putting on a show, it’s about connecting with fans and the powerful exchange that music provides,” says singer-songwriter Sam Roberts. “Music has a unique ability to lift spirts, unite and inspire, and this live music experience wouldn’t be possible without the venues, the fans and the dedicated people behind the scenes who bring it all together.”

The impact of the pandemic has increased the demand for artist content as audiences look for ways to ease the stress of social isolation.  While live businesses have attempted to carry on by producing streamed content, high production costs leave many without resources to access this potential revenue stream. Kinaxis InConcert will provide that support along with opportunities for artists across a diverse range of genres to connect with their audience and get paid for their valuable work.

“We are thrilled to be partnering with the Canadian Live Music Association to sponsor a concert series that will put our talented artist community back on stage, where they belong, and for the venues to bring their music to their fans,” adds Sicard. “After all, music is food for the soul and we could all use as much nourishment as we can get.”      

For more information about Kinaxis InConcert, visit: kinaxis.com/InConcert.

About Canadian Live Music Association
The Canadian Live Music Association (CLMA) is the voice of Canada’s live music industry. Established in response to an identified need in the music industry, the CLMA represents the full spectrum of the live music sector, including concert promoters, festivals, talent agencies, venues, clubs, arenas, performing arts centres, ticketing companies, industry associations and networks, as well as suppliers to the sector. Its mission is to entrench the economic, social and cultural value of live music – creating the conditions for concerts to thrive, from coast to coast to coast.

About Kinaxis Inc.
Everyday volatility and uncertainty demand quick action. Kinaxis® delivers the agility to make fast, confident decisions across integrated business planning and the digital supply chain. People can plan better, live better and change the world. Trusted by innovative brands, we combine human intelligence with AI and concurrent planning to help companies plan for any future, monitor risks and opportunities and respond at the pace of change. Powered by an extensible, cloud-based platform, Kinaxis delivers industry-proven applications so everyone can know sooner, act faster and remove waste. For more Kinaxis news, visit Kinaxis.com or follow us on LinkedIn or Twitter.

SOURCE Kinaxis

Posted on

American Public University System Honors Veterans with Expanded Support of Wreaths Across America

PR Newswire

CHARLES TOWN, W. Va., Dec. 14, 2020 /PRNewswire/ — Highlighting its ongoing commitment to the active duty military and veterans communities, American Public University System (APUS) has expanded support of National Wreaths Across America Day this holiday season. APUS is increasing efforts by:

  • Coordinating the delivery of over 43,300 wreaths in seven tractor-trailer trucks to 28 sites in six states across the United States;
  • Donating funds to an underserved veterans’ cemetery, Killeen City Cemetery, in Killeen, Texas, near Ft. Hood;
  • Coordinating extensive volunteer efforts for over 300 American Military University (AMU) and American Public University (APU) students, faculty, staff and alumni at 10 cemeteries. 

“This meaningful event allows us to pay our respects to those who have fought to preserve our freedom,” said APUS President Dr. Wade Dyke.    

Watch this video to see how APUS has supported the non-profit Wreaths Across America for nearly a decade: https://youtu.be/mRTLJ3SVA-g.

Rob Ahlers, President of MSR Transport Services and an AMU Ambassador, added, “We are honored to have teams driving that are so willing to put money and home-time aside to help ensure that the veterans buried across the country are not forgotten about this holiday season. We’re proud to have seven driving teams delivering wreaths by travelling over 20,000 miles across the nation this year.”

Over the past five years, roughly 2,800 APUS volunteers have participated in National Wreaths Across America Day, which this year takes place on Dec. 19. Last year, the AMU/MSR Transport WAA Honor Fleet drivers delivered nearly 6,200 wreaths to 15 cemeteries. 

“Since becoming a national non-profit in 2007, Wreaths Across America has grown from one tractor trailer load of wreaths to Arlington to more than 600 loads of wreaths traveling to more than 2,500 participating locations this year,” said Don Queeney, Director of Transportation, Wreaths Across America. “To accomplish this mission, we rely on the generosity of our partners who continue to grow with us year after year. American Public University System, in partnership with Rob Ahlers and his network of drivers, have stepped up to cover more cemeteries in New York, Texas, Florida, Georgia and Washington. We are grateful for their continued support.”

To find a veterans cemetery near you to support visit: https://wreathsacrossamerica.org/pages/search.

As the top university nationwide for veterans using their GI Bill benefit (based on student enrollment data), APUS offers over 200 unique, service-minded online degree and certificate programs, affordable tuition, monthly class starts, a scholar-practitioner faculty, and has an ongoing commitment to veterans and military students since AMU was founded in 1991 by a former Marine Corps officer.

Supporting Resources

About American Public University System
A wholly owned subsidiary of American Public Education, Inc. (Nasdaq: APEI), American Public University System offers more than 200 online degree and certificate programs through American Public University and American Military University, the #1 provider of education to the U.S. military* and the top university nationwide for veterans using their GI Bill benefit** (based on student enrollment data). APUS is the recipient of the Online Learning Consortium’s (OLC) Gomory Award for Quality Online Education and five-time recipient of OLC’s Effective Practice Award. Over 101,400 alumni worldwide have benefited from APUS’s inclusive, relevant curriculum and flexible online delivery model. For more information, visit www.apus.edu.

*Based on FY 2019 DoD tuition assistance data, as reported by Military Times, 2020.
**Based on FY 2019 Department of Veterans Affairs (VA) data, as reported by Military Times, 2020.  

CONTACT

Frank Tutalo

Director of Public Relations
571-358-3042
[email protected] 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/american-public-university-system-honors-veterans-with-expanded-support-of-wreaths-across-america-301192120.html

SOURCE American Public University System

Posted on

Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold

Company anticipates Q4 revenue will significantly exceed previous quarter

PR Newswire

SALT LAKE CITY, Dec. 14, 2020 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has sold over 10 million of its Logix Smart™ COVID-19 Test Kits to its domestic and international network of laboratories, hospitals, and distributors.

In conjunction with this milestone, the Company has also announced strong revenue in Q4 anticipated to exceed that of Q3

In conjunction with this milestone, the Company has also announced strong revenue in Q4 2020 anticipated to exceed that of Q3 2020, further underscoring the success of the Company’s business model.

“We are pleased to be able to share this milestone with our shareholders and are proud of what we have been able to accomplish this year, including launching 3 critical COVID-19 tests,” remarked Dwight Egan, CEO of Co-Diagnostics. “These products enable us to address the needs of different countries of the world in the battle against the coronavirus, and to differentiate COVID-19 from influenza which the World Health Organization has estimated may afflict one to 1 billion people per year. To be able to excel in an efficient, profitable manner is a credit to the quality of our patented CoPrimer™ technology platform, our valuable distributor and customer network, and dedication of our growing team of personnel.

“Our achievements over the past year support our belief that we have established a diverse, successful business model that has propelled us into an internationally recognized brand of molecular diagnostics, and that will continue to drive success of our COVID-19 tests other molecular diagnostic tools and applications. Management remains committed to achieving our long-term goals of improving the lives of our customers and their families by providing safe, high quality and cost-effective diagnostics across the globe, as we have already done for millions of people during the coronavirus pandemic.”

In addition to its Logix Smart COVID-19 test, the Company also has regulatory approvals for other in vitro diagnostics including Flu A/Flu B/COVID-19, a SARS-CoV-2 2-gene multiplex test, and a multiplex test for Zika/dengue/chikungunya among others. Co-Diagnostics also markets an array of vector control multiplex products to test mosquito populations for the presence of certain viruses, and is actively developing products for use for liquid biopsy as well as for next-gen sequencing ag-bio applications. The Company’s joint venture in India, CoSara Diagnostics Pvt Ltd, has received CDSCO clearance for RT-PCR tests for COVID-19, a SARS-CoV-2 (2-gene multiplex test), Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) to be manufactured and sold as IVDs in the Indian market.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to rely on any forward-looking statements. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-announces-milestone-of-over-10-million-covid-19-tests-sold-301191945.html

SOURCE Co-Diagnostics

Posted on

Inpixon Releases High-Performance, Real-Time Location System Server Enhancements

NanoLES for UWB and Chirp Delivers RTLS Accuracy, Scalability and Interoperability

Allows Tracking of More Than 10,000 Assets Creating Opportunities for Large-Scale Deployments with Global Enterprise Customers

PR Newswire

PALO ALTO, Calif. and BERLIN, Dec. 14, 2020 /PRNewswire/ — Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced the release of nanoLES 3.3, delivering increased location accuracy, expanded system scalability and interoperability, and enhanced developer tools for use in real-time location systems (RTLS) deployments.

Inpixon’s nanoLES is an advanced location engine server enabling ultra-wideband (UWB) and chirp spread spectrum (CSS) RTLS solutions for real-time positioning of people and devices. Its ability to determine the location of tags multiple times per second makes nanoLES capable of being used in situations where low-latency, real-time determination is a necessity. These use cases include finding an injured worker, avoiding collisions, monitoring parts on a production line, activating ventilation as a worker enters an area, and facilitating turn-by-turn navigation.  The latest version delivers, among other features, improved UWB positional accuracy, a RESTful API architecture for interoperability with IoT platforms and third-party systems, automated performance adaption to the available number of CPU cores, and enhancements to the developer toolkit. 

“Location accuracy, consistency and scalability are critical for our clients’ real-time location use cases,” noted Adam Benson, CTO of Inpixon. “With our latest release, we continue to deliver location precision within centimeters while scaling to more than 10,000 tracked entities. Our patented techniques and methods, including our virtualized time synchronization, enable analyzation of up to 2,500 simultaneous tag data packet ‘blinks’ per second to deliver the location of key people or assets. And our developer toolkit enables efficient configuration and maintenance processes which can speed installation and decrease the total cost of ownership.”

“We are excited to launch these enhancements to nanoLES to further support large-scale RTLS deployments and to meet the growing needs of major enterprise organizations around the world,” said Nadir Ali, CEO of Inpixon. “Centimeters and milliseconds matter when it comes to real-time positioning, and we’re proud to deliver our high-performance RTLS solution for use in a wide range of industries and critical use cases. MarketsandMarkets projects the location-based services (LBS) and real-time location systems (RTLS) market will grow at 17.1% CAGR to $39.2 billion by 2025, and we believe our IP and product portfolios, global customer base, and established developer and distribution partnerships, position us well to achieve significant success in this fast-growing market.”

For more information on Inpixon RTLS solutions, please go to https://nanotron.com/EN/rtls-location-server-software. To speak with a product specialist, please visit https://nanotron.com/EN/ca_contact-php.

About Inpixon

Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that specializes in capturing, interpreting and giving context to indoor data so it can be translated into actionable intelligence. The company’s Indoor Intelligence platform ingests diverse data from IoT, third-party and proprietary sensors designed to detect and position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired with a high-performance data analytics engine, patented algorithms, and advanced mapping technology, Inpixon’s solutions are leveraged by a multitude of industries to do good with indoor data. This multidisciplinary depiction of indoor data enables users to increase revenue, decrease costs, and enhance safety. Inpixon customers can boldly take advantage of location awareness, analytics, sensor fusion and the Internet of Things (IoT) to uncover the untold stories of the indoors. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.

Safe Harbor Statement

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19 on Inpixon’s results of operations, Inpixon’s ability to integrate the products and business from recent acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon’s technology, Inpixon’s ability to maintain compliance with Nasdaq’s minimum bid price requirement and other continued listing requirements, including during a panel monitoring period ending on February 5, 2021, the ability to obtain financing, competition, general economic conditions and other factors that are detailed in Inpixon’s periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.

Inpixon Contacts

Media relations and general inquiries:
Inpixon
Email: [email protected]
Web: inpixon.com/contact-us

Investor relations:
Crescendo Communications, LLC
Tel: +1 212-671-1020
Email: [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inpixon-releases-high-performance-real-time-location-system-server-enhancements-301191712.html

SOURCE Inpixon